HAGE-derived peptide as a vaccine to prevent relapse in TNBC patients: Proof of concepts

      Background: Triple Negative Breast Cancers (TNBC) account for 15% of all breast cancer and are one of the most aggressive type and have poor long-term prognosis. Moreover, there are currently no approved targeted therapies and chemotherapy remains the mainstay of treatment for early and advanced disease. The level of immune infiltrate in TNBC has been linked to a more favourable outcome and lower mutation and neoantigen counts, indicating that an active immune surveillance is ongoing and that these patients might benefit form a combination of checkpoint inhibitor therapy and antigen specific vaccination. We have found that the cancer testis antigen HAGE (DDX43, CT13) is expressed in 43% of patients with TNBC and that it is an independent predictor of a patient’s response to chemotherapy. Therefore, patients with HAGE positive tumours might benefit from a HAGE-specific vaccine.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect